NCT06698588 Symptom-specific Effects of Omega-3 Across Neurodevelopmental Symptoms
| NCT ID | NCT06698588 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Swansea University |
| Condition | Sleep |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-07 |
| Primary Completion | 2025-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-11-07 with a primary completion date of 2025-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Our study aims to determine whether omega-3 fatty acid supplementation can improve sleep, mood, and behavior in children with sleep problems and symptoms of Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), or both. By using a transdiagnostic approach-focusing on specific symptoms rather than diagnostic labels-we aim to identify which children may benefit most from omega-3 supplementation, thereby enhancing inclusivity. Many previous studies have excluded children with both ASD and ADHD, or those without a formal diagnosis.
Eligibility Criteria
Inclusion Criteria: Autism Spectrum Quotient 10 score \>5 OR Conners 3 Handscored Short Parent Form T score \> 64 for either the inattention OR hyperactivity subscales OR Children Sleep Habits Questionnaire SF score \>30 Able to swallow capsules Exclusion Criteria: Any major psychiatric condition likely to require hospitalization (e.g., Psychotic Disorders; Eating Disorders), but NB: for representativeness of typical children with ADHD/ASD, diagnosed mood/anxiety/sleep or other neurodevelopmental disorders will not be exclusion criteria; Severe learning difficulties (e.g., Down syndrome) Any serious medical condition; (d) allergy to any ingredients of the intervention or related substances
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06698588 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 12 Years, studying Sleep. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06698588 currently recruiting?
Yes, NCT06698588 is actively recruiting participants. Contact the research team at h.a.young@swansea.ac.uk for enrollment information.
Where is the NCT06698588 trial being conducted?
This trial is being conducted at Swansea, United Kingdom.
Who is sponsoring the NCT06698588 clinical trial?
NCT06698588 is sponsored by Swansea University. The trial plans to enroll 200 participants.